Abstract
Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol. Young post-myocardial infarction patients, however, usually exhibit a multiplicity of metabolic risk factors with dyslipidaemias, predominantly hypertriglyceridaemia, and disturbances of glucose-insulin homeostasis and of the haemostatic system. These factors, together coupled with coronary angiographic data showing that the degree of dyslipidaemia is related to the extent and degree of coronary atherosclerosis, and the fact that rapid progression of coronary atherosclerosis was foreseen in this group of patients, resulted in the initiation of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) in 1985. BECAIT was a 5-year, double-blind, placebo-controlled study of bezafibrate (200 mg three times daily) and dietary intervention in dyslipidaemic male survivors of myocardial infarction below 45 years of age. The angiographic analysis included 81 patients (42 bezafibrate and 39 placebo) who underwent baseline and at least one pos...Continue Reading
Citations
Jul 14, 2010·Current Atherosclerosis Reports·Peter P Toth
Dec 21, 2000·Current Atherosclerosis Reports·P Duriez, J C Fruchart
Jun 17, 2000·Atherosclerosis·P PauciulloM Mancini
May 30, 1998·Atherosclerosis·C P PalazónL Badimon
Aug 7, 2002·Pharmacology & Therapeutics·Helen VosperColin N A Palmer
Jun 3, 1999·European Journal of Clinical Investigation·A Martínez-Rubio
Dec 5, 2008·Epilepsia·Natacha PortaStéphane Auvin
Aug 29, 2007·International Journal of Nanomedicine·Konstantinos Tziomalos, Vasilios G Athyros
Aug 24, 2010·Vascular Health and Risk Management·Elisavet MoutzouriHaralampos J Milionis
Aug 12, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Genovefa D KolovouDennis V Cokkinos
Apr 15, 2014·PloS One·Navjot KaurSamir Malhotra
Sep 24, 2008·Expert Opinion on Investigational Drugs·Theodosios Filippatos, Haralampos J Milionis
Aug 21, 2012·The Canadian Journal of Cardiology·Pamela M Katz, Lawrence A Leiter
Jul 28, 2006·Trends in Endocrinology and Metabolism : TEM·James F Tobin, Leonard P Freedman
Dec 14, 2006·Prostaglandins & Other Lipid Mediators·Jamie J O'BrienRichard P Phipps
Jul 31, 1998·The American Journal of Medicine·W H Frishman
Nov 20, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·J C FruchartP Duriez
Feb 2, 2010·Journal of the American College of Cardiology·Raffaele De CaterinaRoberto Marchioli
Jul 20, 2001·Medical Hypotheses·M F McCarty
Nov 14, 2006·Medical Hypotheses·Narayan V Nimbkar, Fatimah Lateef
Oct 27, 2015·The Cochrane Database of Systematic Reviews·Deren WangMing Liu
Sep 26, 2019·Angewandte Chemie·Connor W ColeyKlavs F Jensen
Apr 30, 2008·Journal of Biomolecular Screening·Ho Yan Gloria TseShuk Han Cheng
Sep 4, 1999·Annals of Internal Medicine·K J Harjai
Sep 30, 2020·Big Data·Christos KarapiperisChristos A Ouzounis
Oct 20, 2005·The Cochrane Database of Systematic Reviews·R P DellavalleL Schilling
Jun 22, 2002·Progress in Cardiovascular Diseases·John A Farmer, Antonio M Gotto